Company: NOTV
Filing Date: 2025-01-23
Form Type: DEF 14A
Source: 0001628280-25-002250
Chunk: 0

Company: Inotiv, Inc.
Filing Date: 2025-01-23
Form: DEF 14A
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### SCHEDULE 14A INFORMATION
<div align='center'>Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

(Amendment No. )</div>

Filed by the Registrant x

Filed by a party other than the Registrant o

Check the appropriate box:

| o |     | Preliminary Proxy Statement                                                     |
| o |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| x |     | Definitive Proxy Statement                                                      |
| o |     | Definitive Additional Materials                                                 |
| o |     | Soliciting Material under § 240.14a-12                                          |

| Inotiv, Inc.                                                             |
| (Name of Registrant as Specified In Its Charter)                         |
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) |

Payment of Filing Fee (Check all boxes that apply):

| x |     | No fee required                                                                                     |
| o |     | Fee paid previously with preliminary materials                                                      |
| o |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

January 23, 2025

Dear Fellow Shareholders,

Fiscal 2024 presented significant challenges for the preclinical contract research industry, as early-stage drug research and development remained constrained by the lingering effects of the slower biotechnology funding environment throughout 2022 and 2023. Additionally, the non-human primate (NHP) market environment remained challenging, with export restrictions from key suppliers, including those in China and Cambodia, continuing to limit availability. Despite these headwinds, we believe Inotiv was able to navigate these broader market trends and execute on our customer excellence and operational efficiency initiatives, positioning the company well for the future.

Our RMS business results were impacted by reduced demand from certain customers and margin pressure stemming from the timing mismatch between sales and imports. During 2024, we identified new NHP supply sources from multiple countries, strengthening our position for the future. Additionally, we focused on transitioning from spot-market selling to pre-selling our NHP supply, which we anticipate will reduce volatility in the RMS segment during 2025.

In the non-NHP RMS business, growth in our